Background
Rapid influenza diagnostic tests (RIDTs) have an important role in clinical decision-making; however, the performances of currently available assays vary widely.
Influenza and Other Respiratory Viruses | |
Detection of influenza A and B with the Alere™ i Influenza A & B: a novel isothermal nucleic acid amplification assay | |
Briony Hazelton1  Timothy Gray1  Jennifer Ho1  V. Mala Ratnamohan1  Dominic E. Dwyer1  | |
[1] Centre for Infectious Diseases and Microbiology Laboratory Services, Institute for Clinical Pathology and Medical Research, Westmead Hospital, Westmead, NSW, Australia | |
关键词: Influenza; isothermal nucleic acid amplification; rapid diagnostic test(s); sensitivity; specificity; | |
DOI : 10.1111/irv.12303 | |
来源: Wiley | |
Rapid influenza diagnostic tests (RIDTs) have an important role in clinical decision-making; however, the performances of currently available assays vary widely. We evaluated the performance of the Alere™ i Influenza A&B (Alere™ iNAT), a rapid isothermal nucleic acid amplification assay that has recently received FDA clearance, for the detection of influenza A and B viruses during the Australian influenza season of 2013. Results were compared to two other RIDTs tested in parallel; Quidel Sofia® Influenza A+B fluorescent immunoassay (FIA) and Alere™ BinaxNOW® Influenza A & B immunochromatographic (ICT) assay. A total of 202 paired nasopharyngeal swabs collected from patients ≥16 years old with an influenza-like illness (ILI) were eluted in 2 ml of universal transport medium (UTM) that was used to perform all three RIDTs in parallel. Reverse-transcription polymerase chain reaction (RT-PCR) was used as the reference standard. Compared to RT-PCR, Alere™ iNAT detected 77·8% influenza A positive samples versus 71·4% and 44·4% for the Quidel Sofia® Influenza A+B FIA and BinaxNOW® Influenza A & B ICT assay, respectively. For influenza B, Alere™ iNAT detected 75% of those positive by RT-PCR, versus 33·3% and 25·0% for Sofia® and BinaxNOW®, respectively. The specificity of Alere™ iNAT was 100% for influenza A and 99% for influenza B. Alere™ i Influenza A&B is a promising new rapid influenza diagnostic assay with potential point-of-care applications.Abstract
Background
Objectives
Methods
Results
Conclusions
CC BY
© 2015 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.
Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Files | Size | Format | View |
---|---|---|---|
RO202107150012424ZK.pdf | 94KB | download |